ESR1 and breast neoplasm: These results align with the EMERALD subgroup analysis of patients with greater than 12 months on a prior CDK4/6 inhibitor, which showed a median PFS of 5.5 months on elacestrant for breast tumors with dual mutations in ESR1 and PIK3CA (17).